Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.
2.

Can change in high-density lipoprotein cholesterol levels reduce cardiovascular risk?

Dean BB, Borenstein JE, Henning JM, Knight K, Merz CN.

Am Heart J. 2004 Jun;147(6):966-76. Review.

PMID:
15199342
3.

Blood pressure and coronary heart disease: a review of the evidence.

Lawes CM, Bennett DA, Lewington S, Rodgers A.

Semin Vasc Med. 2002 Nov;2(4):355-68. Review.

PMID:
16222626
5.

Consumption of trans fats and estimated effects on coronary heart disease in Iran.

Mozaffarian D, Abdollahi M, Campos H, Houshiarrad A, Willett WC.

Eur J Clin Nutr. 2007 Aug;61(8):1004-10. Epub 2007 Jan 31.

PMID:
17268422
6.

Dietary cholesterol, atherosclerosis and coronary heart disease.

Kratz M.

Handb Exp Pharmacol. 2005;(170):195-213. Review.

PMID:
16596800
7.

Apolipoprotein-B, low-density lipoprotein cholesterol, and the long-term risk of coronary heart disease in men.

St-Pierre AC, Cantin B, Dagenais GR, Després JP, Lamarche B.

Am J Cardiol. 2006 Apr 1;97(7):997-1001. Epub 2006 Feb 13.

PMID:
16563904
8.

Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease.

Liu J, Sempos CT, Donahue RP, Dorn J, Trevisan M, Grundy SM.

Am J Cardiol. 2006 Nov 15;98(10):1363-8. Epub 2006 Sep 29.

PMID:
17134630
9.

Explanation for the Japanese paradox: prevention of increase in coronary heart disease and reduction in stroke.

Ueshima H.

J Atheroscler Thromb. 2007 Dec;14(6):278-86. Epub 2007 Dec 17. Review.

10.

Role of lipid-modifying therapy in the prevention of initial and recurrent stroke.

Hankey GJ.

Curr Opin Lipidol. 2002 Dec;13(6):645-51. Review.

PMID:
12441889
11.

Health effects of trans-fatty acids: experimental and observational evidence.

Mozaffarian D, Aro A, Willett WC.

Eur J Clin Nutr. 2009 May;63 Suppl 2:S5-21. doi: 10.1038/sj.ejcn.1602973. Review.

PMID:
19424218
12.

Cardiovascular disease risk factors in chronic renal insufficiency.

Sarnak MJ, Coronado BE, Greene T, Wang SR, Kusek JW, Beck GJ, Levey AS.

Clin Nephrol. 2002 May;57(5):327-35.

PMID:
12036190
13.

[All mortality by cause of death. The challenge of coronary prevention].

Fernández-Cruz A.

Rev Esp Cardiol. 1998;51 Suppl 6:23-9. Review. Spanish.

14.

Prevalence of coronary heart disease risk factors in Costa Rican adolescents.

Monge R, Beita O.

J Adolesc Health. 2000 Sep;27(3):210-7.

PMID:
10960220
15.

Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial.

Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E; PROVE IT-TIMI 22 Investigators.

J Am Coll Cardiol. 2008 Feb 19;51(7):724-30. doi: 10.1016/j.jacc.2007.10.038.

16.

Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men.

Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB.

Circulation. 2005 Nov 29;112(22):3375-83.

17.
18.

Cholesterol reduction and clinical benefit. Are there limits to our expectations?

Fager G, Wiklund O.

Arterioscler Thromb Vasc Biol. 1997 Dec;17(12):3527-33.

19.

Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease.

Wenger NK, Lewis SJ, Herrington DM, Bittner V, Welty FK; Treating to New Targets Study Steering Committee and Investigators.

Ann Intern Med. 2007 Jul 3;147(1):1-9.

PMID:
17606955
20.

Supplemental Content

Support Center